These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29080252)

  • 21. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma.
    Schrempp DR; Childress MO; Stewart JC; Leach TN; Tan KM; Abbo AH; de Gortari AE; Bonney PL; Knapp DW
    J Am Vet Med Assoc; 2013 Jun; 242(11):1534-8. PubMed ID: 23683018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effects of piroxicam in spontaneous canine invasive urinary bladder cancer, a relevant model of human invasive bladder cancer.
    Knapp DW; Glickman NW; Mohammed SI; DeNicola DB; Widmer WR; Bonney PL; DeGortari AE
    Adv Exp Med Biol; 2002; 507():377-80. PubMed ID: 12664613
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.
    Arnold EJ; Childress MO; Fourez LM; Tan KM; Stewart JC; Bonney PL; Knapp DW
    J Vet Intern Med; 2011; 25(6):1385-90. PubMed ID: 22092632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases.
    Gustafson TL; Biller B
    J Am Anim Hosp Assoc; 2019; 55(5):243-248. PubMed ID: 31433219
    [No Abstract]   [Full Text] [Related]  

  • 25. Prognostic factors in dogs with urinary bladder carcinoma.
    Rocha TA; Mauldin GN; Patnaik AK; Bergman PJ
    J Vet Intern Med; 2000; 14(5):486-90. PubMed ID: 11012109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a one-hour saline diuresis protocol for administration of cisplatin to dogs.
    Ogilvie GK; Fettman MJ; Jameson VJ; Walters LM; Lafferty MH; Cooper MF; Powers BE; Ciekot PA; Atwater SW; Withrow SJ
    Am J Vet Res; 1992 Sep; 53(9):1666-9. PubMed ID: 1416374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder.
    Chun R; Knapp DW; Widmer WR; DeNicola DB; Glickman NW; Kuczek T; Degortari A; Han CM
    J Vet Intern Med; 1997; 11(5):279-83. PubMed ID: 9348494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder.
    Abbo AH; Jones DR; Masters AR; Stewart JC; Fourez L; Knapp DW
    J Vet Intern Med; 2010; 24(5):1124-30. PubMed ID: 20695986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin for treatment of transitional cell and squamous cell carcinomas in dogs.
    Shapiro W; Kitchell BE; Fossum TW; Couto CG; Theilen G
    J Am Vet Med Assoc; 1988 Dec; 193(12):1530-3. PubMed ID: 3215812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microalbuminuria is not associated with cisplatin-induced azotemia in dogs.
    Autio K; Rassnick KM; Goldstein RE; Erb HN
    J Vet Intern Med; 2007; 21(6):1198-202. PubMed ID: 18196726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A combined protocol with piroxicam, chemotherapy, and whole pelvic irradiation with simultaneous boost volumetric modulated arc radiotherapy for muscle-invasive canine urinary transitional cell carcinoma: First clinical experience.
    Malfassi L; Fidanzio F; Sala M; Marcarini S; Mazza G; Carrara N; Pavesi S; Gnudi G; Urso G; Dolera M
    J Vet Med Sci; 2021 Apr; 83(4):695-704. PubMed ID: 32963177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin: a review of toxicities and therapeutic applications.
    Barabas K; Milner R; Lurie D; Adin C
    Vet Comp Oncol; 2008 Mar; 6(1):1-18. PubMed ID: 19178659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin nephrotoxicity in a patient with a single kidney.
    Udeani GO; Singh K; Mullane MR; Lad TE
    Ann Pharmacother; 1996; 30(7-8):782-6. PubMed ID: 8826561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.
    Fukushima K; Okada A; Oe H; Hirasaki M; Hamori M; Nishimura A; Shibata N; Sugioka N
    Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):193-203. PubMed ID: 28913815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development.
    Knapp DW; Ramos-Vara JA; Moore GE; Dhawan D; Bonney PL; Young KE
    ILAR J; 2014; 55(1):100-18. PubMed ID: 24936033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
    Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
    Rossi F; Sabattini S; Vascellari M; Marconato L
    Vet Comp Oncol; 2018 Dec; 16(4):497-504. PubMed ID: 29806156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.
    Maeda S; Sakai K; Kaji K; Iio A; Nakazawa M; Motegi T; Yonezawa T; Momoi Y
    Sci Rep; 2022 Jan; 12(1):4. PubMed ID: 35027594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.